OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2023-05-31-accounts

CHARITY COMMISSION FOR ENGLAND AND WALES Independent examiner's report on the accounts Section A Independent Examiner's Report Report to tho truste Haem8tar'. Haematology Swiality Traning Audit and Research On accounts for the year onded 3110512023 Charoty no (If avy) 1199224 Set out on pag88 I report to the Iruslees on my examination of thè accounts of the ab)ve charity {"Ihe Trusf'l for the year ended 31 May 2023. Respon$ibllltle8 and basls of report As the charity's trustees, you are responsible for the preparatron of the accounts in accordance with the requirements of the Charities Act 2011 I'the Acr). I report in respect of my examination of the Tnjst's accounts carried out under se¢tion 145 of the 2011 Act and in carrying out my examination. I have folk)wed all the applicable Directions given by the Charity Commission under sethon 145151{bl of the Act. Independent I have completed my examination. I confiTh that no material matters have examinerfs statement come lo my attention in connection with the e￿nInation vthi¢h gives me cause lo believe that in, any material respect.. the accounting ￿COrdS were not kept in accordance with section 130 of the Charities Act., or the accounts did not accord vAth the accounting rec(￿￿$.. or the account5 did not Comply with the applicable requirements concerning the fomi and content of accounts set out in the Charities (Accounts and Reports) RegulatKsns 2008 other than any requirement that the accounts give a'lrue and fairf view which is not a matter considered as part of an independent ex8mination. I have no concems and have come across no other matters in connection wth the examination to which attention should te drawn in this report in order to enable a prop8r understanding of the accounts to ￿ rexhed. ' Pleas8 delete the woffls in the brackets rfthgy not apply. Signod: 13 March 2024 Name: Mark Fellows (Willows Awountancy Ltd) Relevant profo88lonal qualifi¢ation(8) or body {11 any): Fellow Member of Association of Accounting Technicians Address: 172 Watling Street, Bridglown. Staffordshire, WS11 OBD IER Oct 2018

HaemSTAR: Haematology Specialty Training Audit and Research

1199224

Receipts and payments accountspts and payments accountsts and payments accountspayments accountsayments accountsyments accountsments accounts

Receipts and payments accountspts and payments accountsts and payments accountspayments accountsayments accountsyments accountsments accounts CC16a For the period 01/04/2022 31/05/2023 To from

Section A Receipts and payments Section A Receipts and payments Section A Receipts and payments
A1 Receipts Unrestricted
funds
to the nearest £		 Restricted funds
to the nearest £		 Endowment
funds
to the nearest £		 Total funds
to the nearest £		 Last year
to the nearest £

AstraZeneca (RAPIDO Milestone 1&2)
18.11.22		 35,200 - - 35,200 -
AstraZeneca(RAPIDO Milestone 3)28.11.22 17,600 - - 17,600 -
- - - - -
- - - - -
- - - - -
- - - - -
- - - - -
- - - - -
Sub total(Gross income for AR) 52,800 - - 52,800 -
A2 Asset and investment sales,
(see table).
-
- -
Sub total - -
Total receipts
A3 Payments
-

Instant Print(Promotional flyers 1.4.22)		 23 -
ISTH Membership and Conference
Registration for Giulia Simini (3.5.22)		 268 -
Wiley. Open access fees for Bull et al. JTH
2022 (4.5.22)		 2,786 -
ISTH Conference Registration for Allie
Delaney (21.6.22)		 240 -
Conference Clearance Center (Open Access
fees for Wilson et al. Hemasphere 2022,
15.7.22)		 543 -
Vistaprint(30.9.22) 45 -
Total Merch (Promotional Pens etc, 18.1.23) 155 -
Rich Buka Expenses(rollerposter,1.3.23) 189 -
Lorna Cain (hotel and subsistance,
HaemSTAR meeting newcastle 3.3.23)		 82
Rich Buka Reimbursement for T-shirt
purchase and Hotel Costs (HaemSTAR
meeting 3.3.23)		 338
Domain renting (Squarespace 6.3.23) 19
Website management(Squarespace 7.3.23) 19
Domain renting (Squarespace 6.4.23) 19
Rich Buka (BSH RAPIDO Poster 19.4.23)
UK SHEENA (BSH Regional Rep Meal Out
24.4.23)
Domain renting (Squarespace 9.5.23)
**Sub total **		 26
250
19 -
5,022 -
A4 Asset and investment
purchases, (see table)
-
-
**Sub total ** - -
Total payments
Net of receipts/(payments)
A5 Transfers between funds
-
47,778 -
- -

CCXX R1 accounts (SS)

26/03/2024

1

A6 Cash funds last year end Cash funds this year end

32,915
-
- 32,915 -
80,693 - - 80,693 -

Section B Statement of assets and liabilities at the end of the period

Categories
Signed by one or two trustees on
behalf of all the trustees
B5 Liabilities
B3 Investment assets
B2 Other monetary assets
B4 Assets retained for the
charity’s own use
B1 Cash funds		 Details
Details
Total cash funds
(agree balances with receipts and payments account(s))
Money in bank account (31.5.23)
Details
Details
Details
Signature		 Unrestricted
funds
Restricted funds
to nearest £
to nearest £
80,693
-
-
-
-
-
80,693
-
OK
OK
Unrestricted
funds
Restricted funds
to nearest £
to nearest £
-
-
-
-
-
-
-
-
-
-
-
-
Fund to which asset
belongs
Cost (optional)
-
-
-
-
-
Fund to which asset
belongs
Cost (optional)
-
-
-
-
-
-
-
-
-
Fund to which
liability relates
Amount due
(optional)
-
-
-
-
-
Print Name		 Endowment
funds
to nearest £
-
-
-
-
OK
Endowment
funds
to nearest £
-
-
-
-
-
-
Current value
(optional)
-
-
-
-
-
Current value
(optional)
-
-
-
-
-
-
-
-
-
When due
(optional)
Date of approval

CCXX R2 accounts (SS)

26/03/2024

2

Trustees' Annual Report for the period

Period start date Period end date From 1 April 2022 To 31 May 2023

Section A Reference and administration details

Charity name

HaemSTAR: Haematology Specialist Training, Audit and Research

Other names charity is known by

HaemSTAR

Registered charity number (if any) 1199224

Charity's principal address Office 129, Institute of Biomedical Research


Office 129, Institute of Biomedical Research
Office 129, Institute of Biomedical Research
Edgbaston
Birmingham
Postcode B15 2TT

Names of the charity trustees who manage the charity

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20		 Trustee name Office (if any) Dates acted if not for whole
year		 Name of person (or body) entitled
to appoint trustee (if any)
PhillipLR Nicolson President
Richard J Buka Chair
Andrew J Doyle Past-President

Names of the trustees for the charity, if any, (for example, any custodian trustees)

Name Dates acted if not for whole year
EmilyMillen
Tom Bull

March 2012

TAR

1

Names and addresses of advisers (Optional information)

Type of adviser Name Address

Name of chief executive or names of senior staff members (Optional information)

Section B Structure, governance and management

Description of the charity’s trusts

Type of governing document

Constitution

Unincorporated Association How the charity is constituted

Appointed by existing trustees Trustee selection methods

Additional governance issues (Optional information)

You may choose to include additional information, where relevant, about:

Section C Objectives and activities

  1. To protect and preserve the health of patients suffering from haematological conditions by:

Summary of the objects of the charity set out in its governing document

March 2012

TAR

2

Summary of the main
activities undertaken for the
public benefit in relation to
these objects (include within
this section the statutory
declaration that trustees have
had regard to the guidance
issued by the Charity
Commission on public
benefit)		 During 1/4/22 to 31/3/23 we conceived, developed, ran, supported and/or
wrote up fourteen projects. All of these projects further our charitable
objects because 1) they all require project management (which is used to
train junior doctors and haematologists in how to be researchers and
principal investigators) and 2) they ultimately result in the publication of
research findings that benefit patients. Projects take several years to
complete from the time of inception. Activities completed 1/4/22 to
31/3/23 are highlighted in red text.
CA-COVID19 (Coagulation Abnormalities in COVID19)
-
Type of study:Retrospective Observational Study.
-
Topic:Laboratory coagulation results and thrombotic and
bleeding complications of patients admitted with COVID-19
-
HaemSTAR role:Conceived and developed by Dr Deepa
Arachchillage from Imperial College in association with
HaemSTAR. Promoted by HaemSTAR. Run utilising the
HaemSTAR network. Data management performed by Imperial
College. Funded by Bayer.
-
Size of study:Data collection completed 2021 (370
collaborators, 26 sites, 5883 patients).
-
Main outcomes:Patients taking oral anticoagulation at time of
diagnosis were more likely to be admitted to the intensive care
unit (ICU). Patients developing thrombosis, major haemorrhage or
multi-organ failure had a higher mortality. There was no difference
in thrombosis rates or mortality between pregnant and non-
pregnant women.
-
Outputs:Two publications in Brit J Haem (Crossette-Thambiah et
al. 2021, Arachchillage et al. 2022).Further publication in
Rheumatology(see ‘Achievements’ below)
ITP Post COVID19 Vaccine
-
Type of study:Retrospective Observational Study.
-
Topic:Timing of onset, clinical characteristics, response to
treatment and outcomes of patients with ITP developing following
COVID19 vaccination.
-
HaemSTAR role:Conceived and developed by Dr Quentin Hill
(Leeds). Run and promoted by the ITP Forum and HaemSTAR.
Data management provided by PHE. Funded by PHE.
-
Size of study:Data collection completed in 2022.
-
Size of Study:No results available as study yet to publish.
-
Main outcomes:Data analysis ongoing.
-
Outputs:yet to publish.
ConNeCT:
-
Type of study:Prospective Observational Study.
-
Topic:Neurological, cognitive and neuropsychiatric complications
of TTP.
-
HaemSTAR role:Conceived and developed by Dr Tina Dutt and
Dr Rebecca Shaw (Liverpool). Run and promoted by the
University of Liverpool and HaemSTAR. Data management
provided by University of Liverpool. Funded by the Bayer
Haemophilia Awards Programme.
-
Size of study:Target of 200 patients and 50 healthy volunteers.
Data collection ongoing (planned completion Feb 2024). 247
patients recruited as of 24/1/24.
-
Main outcomes:Yet to finish data collection.
-
Outputs:Yet to finish data collection.
A2PLS (Anticoagulation in Antiphospholipid Syndrome):
-
Type of study:Retrospective National Audit.

March 2012

TAR

3

March 2012

TAR

4

2SR (Two-Sample Rule Survey)

March 2012

TAR

5

In set up: TXA for HMB in acute VTE Tranexamic acid is an effective antifibrinolytic drug that can reduce heavy menstrual bleeding. Despite excellent safety data showing negligible increased risk of thrombosis across millions of patient years, its use in women with heavy menstrual bleeding who have a recent venous thromboembolic event remains controversial. The goal of this project is to 1) survey clinicians to understand current practice, 2) gather observational data, and 3) work towards a pilot Randomised Control Trial. MATRON (Maternal Audit on ThRombolysis Outcome and DecisioN) Will look at the use of thrombolysis for pregnant women with venous thromboembolism. The aims of the project are to 1) survey clinicians to understand their current practice, and 2) gather observational data. Apixaban thrombo-prophylaxis in multiple myeloma It is recommended that multiple myeloma patients treated with IMIDs such as thalidomide and lenalidomide be offered prophylactic anticoagulation due to the high risk of VTE. We understand that practice in the UK has shifted considerably and despite a lack of evidence, clinicians now favour the use of oral factor anti-Xa inhibitors, often apixaban, for this purpose. The aim of this project is to perform a retrospective, observational study to document thrombosis and bleeding outcomes in patients who receive this treatment compared to those who receive low molecular weight heparin. Patient-led research in sickle cell disease We have formed a working group to develop project ideas in sickle cell disease based on patient-involvement. We hope that this will lead to high quality research that can impact patient management in a meaningful way. Venesection for idiopathic and secondary erythrocytosis The evidence for meaningful benefit of venesection in patients with idiopathic and secondary erythrocytosis is extremely scanty. We understand that practice is highly heterogeneous with some clinicians advocating venesection to maintain haematocrit <0.55 for example, and others not venesecting at all. We aim to 1) understand the variations in practice and the reasons for this, 2) gather retrospective, observational data on the outcomes of patients who are venesected vs not venesected, and 3) work towards a randomised controlled trial. Audit of management of neonatal ITP Neonatal ITP is a rare disease and clinical practice is likely heterogeneous. The aim of this project is to prospectively audit care in such cases focusing on protocols, neonatal management and maternal counselling. FUNDING AWARDS We were able to fund two registrars (Giulia Simini and Allie Delaney) to attend the ISTH Conference in London in 2022 who would have otherwise not been able to attend. OPEN ACCESS FEES We paid for two journal publications that would otherwise have been behind journal paywalls to be open access and thus increase their impact. CONFERENCE

March 2012

TAR

6

In association with Hartley Taylor and the Post ISTH/ASH UK Update meeting we hosted a HaemSTAR Update day on 6/2/23 at The Catalyst in Newcastle. This comprised upates and results on current HaemSTAR projects, keynote talks from experts in the field of sickle cell disease, bleeding and ITP as well as a discussion session about future projects and future direction of HaemSTAR. Very positive feedback. Good industry engagement. Done with free registration and zero cost through industry funding.

Additional details of objectives and activities (Optional information)

You may choose to include further statements, where relevant, about:

Section D Achievements and performance

March 2012

TAR

7

Section D Achievements and performance

Summary of the main achievements of the charity during the year

Funding

Successfully secured grant funding from AstraZeneca for RAPIDO Project £88,000 to be received in 5 installments of £17,600 on completion of various project milestones.

Conference abstracts:

Crossette-Thambiah C, Rajakaruna I, Odho Z, Doyle A, Breen K, Laffan M, Arachchillage DJ. Anticoagulation Practice, Recurrent Thrombosis, and Major Bleeding in Antiphospholipid Syndrome- a Multicentre Observational Study in the United Kingdom. ASH Annual Congress (2022) 140 (Supplement 1): 347 – 349.

Cain L, HaemSTAR collaborators, Morton S. The ‘two sample rule’ in emergency departments: A UK-wide survey of junior doctors/physician associates. BSH Annual Scientific Meeting (2023). https://doi.org/10.1111/bjh.18718

Buka RJ, Pettitt M, Sutton D, Doyle A[3] , Lowe GC, Perry R, Magill L, Alikhan R, Nicolson PLR, HaemSTAR Collaborators. RAPIDO: Results from a UK-wide audit of reversal agents for direct oral anticoagulant associated bleeding. https://doi.org/10.1111/bjh.18720

Publications:

Section E Financial review

March 2012

TAR

8

We do not have a reserve policy. Brief statement of the charity’s policy on reserves Cash in bank at 31/3/23 was £81,007.44 in unrestricted funds. Our committed spending for 2023-24 comprises website hosting fees of approximately £<300 as well as a significant amount of money (but <£80k) for paying for project management support for the RAPIDO project. This is fully funded through the successful AstraZeneca Grant. It is unlikely that this represents any significant financial risk. For 2023-24 we hope to be able to use our funds to further support registrars attending conferences and other academic meetings, to make research publications open access, to run our own conference / meeting and to support research studies. We aim to apply for further funding to be able to fund significantly more people to attend scientific meetings. We intend to start a series of educational events including webinars and podcasts. These are dependent on funding / support from partner organisations. They will not go ahead if we haven’t secured sufficient funding. All the projects currently active are fully funded. To develop the more aspirational elements of the projects in set up we will need to gain significant further grant funding.

Details of any funds materially in deficit

None.

Further financial review details (Optional information)

You may choose to include additional information, where relevant about:

Section F Other optional information

Section G Declaration

The trustees declare that they have approved the trustees’ report above.

March 2012

TAR

9

Signed on behalf of the charity’s trustees

Signature(s) Full name(s) Dr Phillip LR Nicolson Position (eg Secretary, Chair, President etc) Date 24/1/24

March 2012

TAR

10